Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
L'entreprise
L'entreprise
Notre histoire
Notre équipe
Carrières
Partenaires
PUBLICATION
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Accès
Affaires médicales
Accès aux patients
Contactez les affaires médicales
PUBLICATION
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Ressources
Ressources
Dans la presse
Communiqués de presse
Ressources pour les patients
FAQ
PUBLICATION
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Investisseurs
Investisseurs
Aperçu pour les investisseurs
Informations financières
Évènements
PUBLICATION
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism